Diabeton MR is indicated for type II diabetes mellitus in adults.
active substance: gliclazide;
1 tablet contains 60 mg gliclazide;
excipients: lactose, hypromellose, magnesium stearate, maltodextrin, colloidal silicon dioxide.
Hypersensitivity to gliclazide or other sulfonylureas, sulfonamides, or any component of the preparation
For adults only.
The daily dose can vary from 0.5 to 2 tablets (30 to 120 mg per day).
The tablet can be divided into equal parts.
The daily dose should be taken once with breakfast.
Half a tablet or whole tablet (s) should be swallowed whole (do not crush but do not chew).
If the patient has forgotten to take the tablets, the dose should not be increased the next day.
Like all hypoglycemic agents, Diabeton MR 60 mg requires individual dose selection depending on the patient's response to treatment (blood glucose, glycated hemoglobin HbA1c).
Pregnant
As a preventive measure, it is advisable to avoid taking gliclazide during pregnancy.
Children
It is not recommended to prescribe Diabeton MR 60 mg to children due to the lack of data on the use of the preparation in this category of patients.
Drivers
Diabeton MR 60 mg may have little effect on the ability to drive vehicles or work with other automated systems. Patients should be aware of the symptoms of hypoglycemia, be able to recognize them and, if they occur, be careful while driving or operating machinery, especially at the beginning of treatment.
Overdose of sulfonylurea preparations can cause hypoglycemia.
Symptoms of moderate hypoglycemia (without loss of consciousness and without neurological symptoms) should be corrected with carbohydrate (sugar) intake, dose adjustment of the antihyperglycemic preparation, and / or diet. Careful observation of the patient should be continued until the physician is confident that the patient is safe.
Severe hypoglycemia may develop with the development of coma, seizures, or other neurological disorders, which requires urgent medical attention with immediate hospitalization.
When a diagnosis of hypoglycemic coma is established or if a coma is suspected, the patient needs to rapidly intravenously inject 50 ml of concentrated glucose solution (from 20% to 30%), followed by continuous administration of a less concentrated glucose solution (10%) at a frequency that will maintain the glucose level in blood more than 1 g / l. It is necessary to ensure constant monitoring of the patient. Depending on the patient's condition, the doctor decides on further monitoring.
Gliclazide has a high level of binding to plasma proteins, so dialysis is ineffective.
The most common adverse reaction with gliclazide is hypoglycemia.
Miconazole (for systemic use, oral gel) enhances the hypoglycemic effect with the possible development of symptoms of hypoglycemia and even the development of coma.
Does not require special storage conditions. Keep out of the reach of children.
Shelf life. 3 years.
There are no reviews for this product.